Best-in-class treatment for Wilson’s disease
Orphalan was incorporated in 2011 to reposition drugs in orphan diseases by exploiting untapped academic research and existing clinical data. The lead indication is Wilson’s disease which results from the toxic accumulation of copper in the body.
Current treatments are not satisfactory due to harmful side effects or complex drug handling requirements. Orphalan has developed a best in class molecule to address this unmet medical need.
CEO Naseem Amin
Advent Contact Alain Huriez
Advent was the sole institutional investor in the Series A in 2015.
Private Companies
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
Press Release. Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the…
Read More
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
Press Release. – Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine – Oral administration…
Read More
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
Press Release. Paris, France 2 May 2022 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialisation company, today announces approval of Cuvrior™, a new…
Read More
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease
Press Release. NDA supported by positive data from Phase 3 CHELATE clinical trial TETA 4-HCl previously granted Orphan Drug Designation for first-line treatment of Wilson’s Disease Paris, France –…
Read More
